T1	Participants 50 148	advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
T2	Participants 255 368	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
T3	Participants 967 1138	Breakdown of disease stage was 7.8% stage III, 22.8% stage IV, and 69.4% recurrent disease. Histologic distribution was 18% S, 3.7% CC, 8.5% mixed, 51.7% E and 18.1% other
